Benchmark analyst Bill Sutherland lowered the firm’s price target on Amedisys to $120 from $135 and keeps a Buy rating on the shares as the firm lowers its 2023 model to below consensus. They expect a largely in-line Q4 report and now look for 2023 AEBITDA to be slightly less than flat compared to 2022, adding that shares are still trading at a discount to the median peer group valuation on their "now more conservative" 2023 estimates.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMED:
- Amedisys price target lowered to $115 from $140 at Credit Suisse
- Amedisys to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Computerworld Names Amedisys to 2023 List of Best Places to Work in IT
- Amedisys closes on home health JV with University of Arkansas
- Amedisys Completes Home Health Joint Venture with the University of Arkansas for Medical Sciences
